Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET

Company Participants

Sarah Mathieson - Senior Vice President-Corporate Affairs

David Cory - President & Chief Executive Officer

Ingrid Choong - Senior Vice President-Clinical Development

Eldon Mayer - Chief Commercial Officer

Sri Ryali - Chief Financial Officer

Colleen Craig - Vice President-Metabolic Diseases

Conference Call Participants

Ashik Mubarack - Citi

Bert Hazlett - BTIG

Luke Herrmann - Baird

Michael Higgins - Ladenburg Thalmann

Operator

Good day, ladies and gentlemen, and welcome to the Eiger BioPharmaceuticals First Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call will be recorded.

I would now like to introduce Sarah Mathieson, Senior Vice President of Corporate Affairs at Eiger. You may begin.

Sarah Mathieson

Thank you. Good afternoon, everyone and thank you for joining us today. Welcome to our quarterly financial results and business update call. We issued a press release earlier this afternoon with our Q1 financial results, which is also available on our website at eigerbio.com.

For today's call, we will have prepared remarks from the management team followed by Q&A. We will use slides for the webcast and a replay will be available on the Investors section of our website.

Joining me on the call with prepared remarks are David Cory, President and CEO; Sri Ryali, Chief Financial Officer; Eldon Mayer, Chief Commercial Officer; and Dr. Ingrid Choong Senior Vice President of Clinical Development. We also have subject matter experts on our team Dr. Colin Hislop and Dr. Colleen Craig available for Q&A.

Before we begin, I would like to remind investors that this call will include forward-looking statements, including expectations concerning financial performance, commercial products and potential future products in different therapeutic areas and stages of development. The forward-looking statements rely on certain assumptions and involve risks and uncertainties beyond Eiger's control, which could cause our actual results to differ materially.

A description of these risks and uncertainties is contained in Eiger’s filings with the SEC including our latest 10-K and 10-Q reports available on the Eiger website in the Investors Section. All forward-looking statements are based on information currently available to Eiger and we assume no obligation to update these statements.

I will now turn the call over to David.